12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

Curis, LLS deal

Curis will receive up to $4 million from the society to fund about 50% of the development costs for Curis' CUDC-907 in B cell lymphoma and multiple myeloma (MM). The...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >